Ipsen
Ipsen is a biopharmaceutical company active in oncology, rare disease, and neuroscience, listed on Euronext Paris as IPN. Its established toxin franchise centers on Dysport. (Ipsen corporate and financial update 🔗)
Ipsen Biopharm Ltd. manufactures Dysport in Wrexham, United Kingdom, and holds the Dysport registered trademark. The U.S. prescribing information names both Ipsen Biopharmaceuticals, Inc. and Galderma Laboratories, L.P. as distributors. Manufacturing, trademark ownership, and commercial distribution are distinct roles. (DailyMed Dysport prescribing information 🔗)
Galderma commercializes aesthetic Dysport-family products in licensed territories. Its January 2026 statement confirmed that termination of an early-stage R&D partnership with Ipsen did not affect commercialization of its existing portfolio under the companies’ agreements. (Galderma partnership and commercialization statement 🔗)
Quick Answers
Section titled “Quick Answers”| Question | Short answer |
|---|---|
| Who makes Dysport? | Ipsen Biopharm Ltd., Wrexham, UK, is the manufacturer named in the U.S. label. |
| Who owns the Dysport trademark? | Ipsen Biopharm Limited. Trademark ownership is separate from licensed commercialization rights. |
| Is Dysport a Galderma product? | Galderma commercializes aesthetic Dysport in licensed markets; that commercial role does not make it the manufacturer. |
| Are Azzalure and Alluzience the same presentation? | No. UK product information describes Azzalure as a powder and Alluzience as a solution for injection. |
| Is corabotase another name for Dysport? | No. Corabotase, also called IPN10200, is a separate investigational recombinant molecule. |
Reference Card
Section titled “Reference Card”| Field | Reference point |
|---|---|
| Company | Ipsen |
| Website | Ipsen official website 🔗 |
| Listing | Euronext Paris: IPN; U.S. sponsored Level I ADR: IPSEY (Ipsen listing disclosure 🔗) |
| Dysport manufacturer | Ipsen Biopharm Ltd., Wrexham, UK (U.S. Dysport label 🔗) |
| Marketed toxin family | Dysport, Azzalure, and Alluzience, with product- and country-specific labels |
| Aesthetic commercialization partner | Galderma in licensed territories (Galderma agreement context 🔗) |
Dysport, Azzalure, And Alluzience
Section titled “Dysport, Azzalure, And Alluzience”The Dysport family spans therapeutic and aesthetic markets, but regional brand names do not establish identical presentations or a universal approval.
| Product | Presentation and regulatory context | Ipsen relationship |
|---|---|---|
| Dysport | U.S. abobotulinumtoxinA; powder requiring reconstitution. Its label covers adult cervical dystonia, specified adult glabellar lines, and spasticity from age 2. (U.S. prescribing information 🔗) | Manufactured by Ipsen Biopharm Ltd. |
| Azzalure | UK aesthetic botulinum toxin type A powder for solution for injection. (UK Azzalure product information 🔗) | UK leaflet names Ipsen Limited as authorization holder, Ipsen Biopharm Limited as manufacturer, and Galderma UK as distributor. (Azzalure patient leaflet 🔗) |
| Alluzience | UK aesthetic botulinum toxin type A solution for injection, rather than powder for reconstitution. (UK Alluzience product information 🔗) | UK leaflet names Ipsen Biopharm Limited as authorization holder and manufacturer. (Alluzience patient leaflet 🔗) |
These UK examples distinguish legal entities and presentations; they do not establish the authorization holder or approved uses in every country. Galderma’s commercialization agreements cover the relevant approved territories rather than conferring one worldwide label.
Dysport Migraine Development
Section titled “Dysport Migraine Development”On July 9, 2026, Ipsen announced positive topline results from its Phase III BEOND program in adults with episodic or chronic migraine. Both placebo-controlled trials met the primary endpoint: change in monthly migraine days at week 24, measured over weeks 21–24. The announcement said detailed findings would be presented at a future scientific congress. (Ipsen BEOND Phase III announcement 🔗)
Ipsen’s October 22, 2026 update described migraine regulatory submissions as underway. That is a development and filing milestone, not an approval announcement. (Ipsen regulatory update 🔗) Migraine is not listed among the indications in the U.S. Dysport prescribing information linked above.
Corabotase: A Separate Investigational Program
Section titled “Corabotase: A Separate Investigational Program”Corabotase (IPN10200) is Ipsen’s investigational recombinant neuroinhibitor, engineered with a type A catalytic domain and a type B binding domain. It is distinct from marketed Dysport / abobotulinumtoxinA. Ipsen’s May 14, 2026 announcement described Phase II LANTIC development in upper facial lines and a broader Phase II/III program across aesthetic and therapeutic indications. (Ipsen corabotase announcement 🔗)
The A/B domain description concerns the engineered molecule’s structure; it does not make corabotase interchangeable with established type A or type B products. Botulinum toxin type A and type A versus type B provide the broader toxin-type context.
Galderma Agreements And Arbitration
Section titled “Galderma Agreements And Arbitration”Two separate disputes affect interpretation of the Ipsen–Galderma relationship:
- January 21, 2026 — R&D agreement: Ipsen announced a final ICC arbitral decision upholding termination of the 2014 R&D agreement and confirming its rights to clinical-stage aesthetic toxin programs. (Ipsen R&D arbitration announcement 🔗) Galderma separately confirmed that the decision did not affect commercialization of its existing neuromodulator portfolio.
- September–October 2026 — further proceedings: Galderma dates its ICC and AAA filings to September 29 and describes them as concerning aesthetic rights and the LANTIC program, excluding Dysport/Azzalure, Alluzience, and Relfydess. (Galderma nine-month update 🔗) Ipsen’s October 22 update describes proceedings initiated in October concerning corabotase and distribution agreements, with outcome and financial impact uncertain. (Ipsen arbitration disclosure 🔗)
The January ruling does not resolve the later proceedings. Neither dispute establishes a clinical advantage for a toxin product.
Dysport Commercial Scale
Section titled “Dysport Commercial Scale”For the nine months ended September 30, 2026, Ipsen reported Dysport sales of €658.5 million, up 18.0% as reported and 19.0% at constant exchange rates, which remove currency movements from the growth comparison. The disclosed split was €415.9 million in aesthetics and €242.7 million in therapeutics; rounded components may not sum to the total. These are Ipsen-reported sales, not Galderma’s downstream sales or a combined global market total. (Ipsen nine-month results, attached sales table on page 4 🔗)
Related People
Section titled “Related People”Ipsen’s leadership directory 🔗 identifies the current executive roles below; historical production work belongs to a separate period.
| Person | Why the relationship matters |
|---|---|
| Olivia Brown | Executive Vice President, Global Head of Neuroscience and Aesthetics, connecting the marketed franchise with the broader business. |
| Christelle Huguet | Executive Vice President, Head of R&D, connecting Dysport migraine and corabotase development with Ipsen’s research organization. |
| Peter Hambleton, Ph.D. | CAMR / Porton Down researcher involved in the therapeutic-toxin production pathway preceding the later Dysport commercial structure. (Cambridge history of botulinum toxin therapy 🔗) |
Label And Comparison Limits
Section titled “Label And Comparison Limits”Dysport potency units are product-specific and cannot be directly compared with or converted into units of other botulinum toxin preparations. Its U.S. label also carries a boxed warning about distant spread of toxin effect, including potentially life-threatening swallowing and breathing problems. (DailyMed Dysport warnings and unit limitations 🔗) Company size, commercial rights, and investigational results do not establish dose equivalence or clinical superiority.

